Theravance (TBPH) news

Theravance Biopharma acquisition by Zymeworks to close in 2H

Zymeworks Inc. (Nasdaq: ZYME) has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (Nasdaq: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million. The transaction is expected to close in the second half of 2026, subject to customary…

Theravance Biopharma Q2 EPS USD -0.11

Theravance Biopharma Inc: H.C. Wainwright cuts to neutral rating

H.C. Wainwright recently adjusted its rating for Theravance Biopharma Inc (NASDAQ:TBPH), moving from a Buy to a neutral stance while raising its price target to $27 from $20. This update follows progress in the company’s CYPRESS trial, with data expected by the end of the first quarter of 2026. The…

Theravance Biopharma Inc: BTIG cuts to neutral from buy

Theravance Biopharma Inc. (NASDAQ: TBPH) has seen recent adjustments in analyst ratings, with BTIG revising its stance from "Buy" to "Neutral" while maintaining a price target of $21. This change follows the company’s announcement of organizational restructuring aimed at reducing operating expenses…

Theravance Biopharma shares fall 3.5% to $17.01 after co to be acquired by Zymeworks for $17 per share in cash

Theravance Biopharma (Nasdaq: TBPH) shares declined 3.5% in pre-market trading to $17.01, following the announcement that Zymeworks Inc. has agreed to acquire the company for $17.00 per share in cash, representing an equity value of approximately $929 million . The transaction, which is subject to…